Green Alpha Advisors LLC Boosts Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Green Alpha Advisors LLC boosted its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 69.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 28,674 shares of the company's stock after purchasing an additional 11,774 shares during the quarter. Green Alpha Advisors LLC's holdings in Moderna were worth $813,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Norges Bank bought a new stake in shares of Moderna in the fourth quarter valued at about $163,833,000. Voloridge Investment Management LLC increased its position in Moderna by 335.6% during the 4th quarter. Voloridge Investment Management LLC now owns 2,590,831 shares of the company's stock valued at $107,727,000 after purchasing an additional 1,996,003 shares during the period. FMR LLC increased its position in Moderna by 7.4% during the 4th quarter. FMR LLC now owns 18,664,634 shares of the company's stock valued at $776,075,000 after purchasing an additional 1,282,469 shares during the period. Pictet Asset Management Holding SA increased its position in Moderna by 170.5% during the 4th quarter. Pictet Asset Management Holding SA now owns 1,766,398 shares of the company's stock valued at $73,447,000 after purchasing an additional 1,113,455 shares during the period. Finally, Invesco Ltd. increased its position in Moderna by 24.3% during the 4th quarter. Invesco Ltd. now owns 5,006,462 shares of the company's stock valued at $208,169,000 after purchasing an additional 979,858 shares during the period. 75.33% of the stock is owned by institutional investors.

Moderna Trading Down 3.2%

Shares of NASDAQ:MRNA traded down $0.86 on Thursday, reaching $26.41. The company had a trading volume of 5,050,225 shares, compared to its average volume of 8,227,684. Moderna, Inc. has a 52-week low of $23.15 and a 52-week high of $158.82. The firm's 50 day simple moving average is $26.23 and its 200-day simple moving average is $33.71. The firm has a market capitalization of $10.21 billion, a PE ratio of -2.85 and a beta of 1.86.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.92) by $0.40. Moderna had a negative return on equity of 28.74% and a negative net margin of 110.04%. The business had revenue of $108.00 million for the quarter, compared to the consensus estimate of $130.35 million. During the same period last year, the business posted ($3.07) EPS. The business's revenue was down 35.3% compared to the same quarter last year. As a group, equities research analysts predict that Moderna, Inc. will post -9.61 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Evercore ISI decreased their target price on Moderna from $50.00 to $32.00 and set an "in-line" rating for the company in a research report on Friday, May 2nd. Bank of America decreased their target price on Moderna from $41.00 to $34.00 and set an "underperform" rating for the company in a research report on Tuesday, February 11th. Royal Bank of Canada decreased their target price on Moderna from $32.00 to $28.00 and set a "sector perform" rating for the company in a research report on Friday, May 2nd. William Blair reaffirmed a "market perform" rating on shares of Moderna in a research report on Monday. Finally, UBS Group decreased their target price on Moderna from $78.00 to $70.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Four equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $53.58.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.